Table 4.
Pharmacokinetic parameters following single and continuous dosing of axitinib (Study 2; N = 6)
| Single dosing | ||||
| Dose | Meana (%CV) | Meana (%CV) | Meana (%CV) | Median (min, max) |
| Cmax, ng/mL | AUCInf, ng·hr/mL | t1/2, h | Tmax, h | |
| 5 mg | 17.0 (70) | 142 (86) | 4.8 (59) | 4.10 (3.95, 6.02) |
| 7 mg | 23.3 (88) | 181 (80) | 5.1 (51) | 4.00 (0.983, 9.88) |
| 10 mg | 34.9 (115) | 288 (91) | 5.9 (59) | 4.02 (2.05, 6.00) |
| Continuous dosing (cycle 1 day 15) | ||||
| Dose | Meana (%CV) | Meana (%CV) | Median (min, max) | Meana (%CV) |
| Cmax, ng/mL | AUC12, ng·hr/mL | Tmax, h | Rac | |
| 5 mg BID | 21.4 (84) | 138 (78) | 4.04 (3.93, 7.70) | 1.37 (28) |
a Values are measured in geometric mean for Cmax, AUCinf, AUC12, and Rac and arithmetic mean for t1/2
%CV percent coefficient of variation; AUC 12 area under the plasma concentration–time curve from time zero to 12 h; AUC Inf area under the plasma concentration–time curve from time zero to infinity; BID twice daily; C max maximum plasma concentration; R ac accumulation ratio; t 1/2 terminal-phase plasma half-life; T max time to first occurrence of Cmax